1. Eli Lilly Commits Up to $2.25B for AI-Designed Gene Editors in Strategic Push into Genetic Medicine
Eli Lilly has entered a collaboration with AI-focused biotech Profluent to develop next-generation gene editors capable of inserting entire genes into patients, signaling a major escalation in the pharmaceutical giant's ambitions in genetic medicine. The deal structure includes up to $2.25 billion in milestone payments...